

L3-2622 Project phases and realization

WP	Main objectives	Months					
		6	12	18	24	30	36
1.1.	Study group 1 patient inclusion, sample and data collection	█		█		█	
1.2.	Study group 1, sample preparation and storage	█		█		█	
2.1.	Study group 2 patient inclusion, sample and data collection	█	█	█			
2.2.	Study group 2, sample preparation and storage	█	█	█			
3.1	<i>PDCD1</i> and <i>CD274</i> genotyping	█	█	█			
3.2	Statistical evaluation of immune checkpoint SNPs as biomarker	█	█	█			
4.1.	Telomere length measurement		█	█	█		
4.2.	<i>hTERT</i> genotyping		█	█	█		
4.3.	Statistical modeling of telomere length and dynamics			█	█	█	█
5.1.	Measurement of calretinin serum levels	█	█	█			
5.2.	<i>CALB2</i> related genotyping	█	█	█			
5.3.	Statistical evaluation of calretinin as biomarker		█	█	█		
6.1.	Isolation of EVs and total RNA		█	█	█		
6.2.	EV miRNA profiling and qPCR validation, Study group 1			█	█	█	
6.3.	EV miRNA profiling and qPCR validation, Study group 2			█	█	█	
6.4.	qPCR validation of diff. expressed miRNAs in plasma				█	█	
6.5.	Statistical modelling of miRNA levels and patient outcomes					█	█
7.1.	Multivariate predictive model of risk for MM development				█	█	█
7.2.	Multivariate predictive model of MM treatment response				█	█	█
8.1.	Communication with co-financer, reporting		█		█		█
8.2.	Activities for Assoc. of Pts. with Asbestos Related Diseases	█	█	█	█	█	█
8.3.	Reporting, dissemination, education	█	█	█	█	█	█